GlassScriptPhysician profile
Brian M Rabon
NPI 1619965027
$1,435.11
in general payments reported to CMS, 2019-2025
18 companies · $413 in 2025
The $413 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $83.13 · 2021: $31.75 · 2022: $31.29 · 2023: $99.88 · 2024: $636 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $575.93 | 2023-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $184.54 | 2019-2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $124.59 | 2019-2024 | |
| Intuitive Surgical, INC. | $90.96 | 2024 | |
| Neos Therapeutics, LP | $87.33 | 2023-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sanofi Pasteur INC. | $65.94 | 2019-2025 | |
| Becton, Dickinson and Company | $40.46 | 2025 | Arista |
| Tris Pharma INC | $37.20 | 2019-2025 | Dyanavel Xr |
| Aytu Biopharma, INC. | $36.88 | 2024 | Karbinal |
| Sobi, INC | $34.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.75 | 2021 | |
| Seqirus USA INC | $26.08 | 2025 | Flucelvax |
| Astrazeneca Pharmaceuticals LP | $25.79 | 2024 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $17.40 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $15.97 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $14.00 | 2025 | Ycanth |
| Merck Sharp & Dohme LLC | $13.93 | 2022 | |
| Pfizer INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Rabon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.